Skip to main content
. 2021 Jul 20;13(14):3642. doi: 10.3390/cancers13143642

Figure 3.

Figure 3

Validation of biomarker candidates in the pretreatment LARC set. (A). Levels of VEGFR3, CTSB, IGFBP4, CEA, EGFR, Ki-67, COX2, and E-cadherin in plasmas collected before nCRT from LARC patients who achieved pCR (pCR; n = 6) and LARC patients who had residual tumors after nCRT (non-pCR; n = 28). Horizontal lines indicate mean and standard deviation. p values were calculated using Welch’s t-test. (B). Receiver operating characteristic curves for VEGFR3, EGFR, COX2, and their combination in the pretreatment LARC set. CEA: Carcinoembryonic antigen, EGFR: Epidermal growth factor receptor, COX2: Prostaglandin G/H synthase 2, AUC: the area under the curve.